-
公开(公告)号：US10857164B2
公开(公告)日：2020-12-08
申请号：US16589699
申请日：2019-10-01
IPC分类号： A61K31/609 , A61K31/612 , A61P31/04 , A61K45/06
摘要： The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.
-
公开(公告)号：US20200093839A1
公开(公告)日：2020-03-26
申请号：US16589699
申请日：2019-10-01
IPC分类号： A61K31/609 , A61K31/612 , A61P31/04 , A61K45/06
摘要： The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.
-
公开(公告)号：US20210308153A1
公开(公告)日：2021-10-07
申请号：US17091691
申请日：2020-11-06
IPC分类号： A61K31/609 , A61K31/612 , A61P31/04 , A61K45/06
摘要： The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.
-
-
搜索结果
3 条记录 (耗时 0.012 秒)
